Gregg Polansky

Array ( [id] => 18314114 [patent_doc_number] => 11628174 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2023-04-18 [patent_title] => Pharmaceutical compositions and methods for treating insomnia [patent_app_type] => utility [patent_app_number] => 17/861070 [patent_app_country] => US [patent_app_date] => 2022-07-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 2 [patent_no_of_words] => 4539 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17861070 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17503376 [patent_doc_number] => 20220096478 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-31 [patent_title] => AMORPHOUS SOLID DISPERSIONS OF DASATINIB AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/545370 [patent_app_country] => US [patent_app_date] => 2021-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33090 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17545370 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17525690 [patent_doc_number] => 11298356 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2022-04-12 [patent_title] => Amorphous solid dispersions of dasatinib and uses thereof [patent_app_type] => utility [patent_app_number] => 17/545324 [patent_app_country] => US [patent_app_date] => 2021-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 33114 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17545324 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17858515 [patent_doc_number] => 11439653 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2022-09-13 [patent_title] => Fospropofol formulations [patent_app_type] => utility [patent_app_number] => 17/466016 [patent_app_country] => US [patent_app_date] => 2021-09-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 11144 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17466016 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17952417 [patent_doc_number] => 11478490 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2022-10-25 [patent_title] => Fospropofol formulations [patent_app_type] => utility [patent_app_number] => 17/387059 [patent_app_country] => US [patent_app_date] => 2021-07-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 16503 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17387059 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17695889 [patent_doc_number] => 11369590 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-06-28 [patent_title] => PSMA binding ligand-linker conjugates and methods for using [patent_app_type] => utility [patent_app_number] => 17/359277 [patent_app_country] => US [patent_app_date] => 2021-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 37 [patent_no_of_words] => 22385 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 99 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17359277 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17569869 [patent_doc_number] => 11318121 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-05-03 [patent_title] => PSMA binding ligand-linker conjugates and methods for using [patent_app_type] => utility [patent_app_number] => 17/359314 [patent_app_country] => US [patent_app_date] => 2021-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 37 [patent_no_of_words] => 22247 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 117 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17359314 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17213170 [patent_doc_number] => 20210346506 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-11 [patent_title] => PRODRUG OF ITRACONAZOLE AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/308160 [patent_app_country] => US [patent_app_date] => 2021-05-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17281 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17308160 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17306252 [patent_doc_number] => 11207334 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2021-12-28 [patent_title] => Fospropofol formulations [patent_app_type] => utility [patent_app_number] => 17/217656 [patent_app_country] => US [patent_app_date] => 2021-03-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 11118 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17217656 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17005328 [patent_doc_number] => 20210236489 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-05 [patent_title] => AMORPHOUS SOLID DISPERSIONS OF DASATINIB AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/206823 [patent_app_country] => US [patent_app_date] => 2021-03-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33056 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17206823 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16939858 [patent_doc_number] => 11052073 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2021-07-06 [patent_title] => Sphingosine kinase 2 inhibitor for treating coronavirus infection [patent_app_type] => utility [patent_app_number] => 17/195279 [patent_app_country] => US [patent_app_date] => 2021-03-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 16205 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17195279 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18151970 [patent_doc_number] => 11564919 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2023-01-31 [patent_title] => Small molecule inhibitors for treatment of alpha viruses [patent_app_type] => utility [patent_app_number] => 17/189596 [patent_app_country] => US [patent_app_date] => 2021-03-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 15 [patent_no_of_words] => 10329 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17189596 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17065737 [patent_doc_number] => 20210267952 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-02 [patent_title] => TREATMENT OF HUMAN CORONAVIRUS INFECTIONS USING ALPHA-GLUCOSIDASE GLYCOPROTEIN PROCESSING INHIBITORS [patent_app_type] => utility [patent_app_number] => 17/180140 [patent_app_country] => US [patent_app_date] => 2021-02-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36766 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17180140 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16805972 [patent_doc_number] => 20210128525 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-06 [patent_title] => TREATMENT FOR PRIMARY BILIARY CHOLANGITIS [patent_app_type] => utility [patent_app_number] => 17/147829 [patent_app_country] => US [patent_app_date] => 2021-01-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13495 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17147829 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17672597 [patent_doc_number] => 20220185764 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-16 [patent_title] => Resveratrol derivative and anti-fibrotic method using the same [patent_app_type] => utility [patent_app_number] => 17/118318 [patent_app_country] => US [patent_app_date] => 2020-12-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4475 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 96 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17118318 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17109999 [patent_doc_number] => 20210290596 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-23 [patent_title] => NEW USE OF ANGIOTENSIN II TYPE 2 RECEPTOR AGONIST [patent_app_type] => utility [patent_app_number] => 17/113416 [patent_app_country] => US [patent_app_date] => 2020-12-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7305 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17113416 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17065733 [patent_doc_number] => 20210267948 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-02 [patent_title] => TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 17/096576 [patent_app_country] => US [patent_app_date] => 2020-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20972 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17096576 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16612068 [patent_doc_number] => 20210030721 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-04 [patent_title] => METHODS FOR TREATING CONGENITAL DISORDERS OF GLYCOSYLATION [patent_app_type] => utility [patent_app_number] => 17/064441 [patent_app_country] => US [patent_app_date] => 2020-10-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10949 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17064441 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16570546 [patent_doc_number] => 20210009552 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-14 [patent_title] => METHODS FOR TREATING PROTOZOAN INFECTIONS [patent_app_type] => utility [patent_app_number] => 17/038690 [patent_app_country] => US [patent_app_date] => 2020-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36221 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17038690 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18368070 [patent_doc_number] => 11648217 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-05-16 [patent_title] => Use of histone acetyltransferase inhibitor amidoximes as anti-proliferative agents [patent_app_type] => utility [patent_app_number] => 17/008617 [patent_app_country] => US [patent_app_date] => 2020-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 23 [patent_no_of_words] => 9271 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17008617 [rel_patent_id] =>[rel_patent_doc_number] =>)